We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Welcomes Expanded Definition of Biosimilars
A small provision in Congress’ bipartisan budget deal expanding the definition of biosimilars has received praise from the FDA, who said the move could help improve access to insulin and other protein products.